RayKnowChina Research Map
Shortlist0

RecruitingMyasthenia gravisPhase 1

Registered title, quoted from ClinicalTrials.gov

Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

An open trial on myasthenia gravis, registered on ClinicalTrials.gov. Led by Tangdu Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Tangdu Hospital空军军医大学唐都医院Xi'anHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06371040, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Male study participants must agree to take contraceptive measures during the treatment period and within 1 year after receiving study treatment, and are prohibited from donating sperm throughout the study period;

    Inclusion criterion 12

    If you are a woman of childbearing potential (WOCBP), you must agree to take contraceptive measures during treatment and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result during screening; a negative urine pregnancy test result must be confirmed before receiving CART for the first time.

    Inclusion criterion 13

    Women who are lactating or pregnant, or women who plan to become pregnant at any time within 12 months after receiving CART treatment, or who have a history of spontaneous abortion or induced abortion within 4 weeks before screening;

    Exclusion criterion 3

    Study participants have received rituximab treatment within 6 months before screening;

    Exclusion criterion 7

    Have received tocilizumab or eculizumab treatment within 3 months before screening;

    Exclusion criterion 8

    Have received intravenous human immunoglobulin, plasma exchange, or immunotherapy within 4 weeks before screening;

    Exclusion criterion 9

  3. Elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN)).

    Exclusion criterion 13

    Total bilirubin>1.5 times ULN

    Exclusion criterion 14

    Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2

    Exclusion criterion 15

    Abnormal PT or INR, or prolonged APTT >1.5 times ULN

    Exclusion criterion 16

    Neutrophil count <1000cell/ul

    Exclusion criterion 17

    Platelet count <50000/mm3

    Exclusion criterion 18

    Hemoglobin<8.0g/dl

    Exclusion criterion 19

  4. Known immunodeficiency diseases, including human immunodeficiency virus (HIV) infection;

    Exclusion criterion 21

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06371040, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Study participants will be selected for this study only if they meet all of the following criteria:
  • Age ≥18 years old and ≤80 years old;
  • The subject signs the informed consent form, is willing and able to comply with the protocol, complete the research assessment and return for follow-up;
  • To be diagnosed as a patient with systemic MG, the patient is required to have positive myasthenia-related antibodies (AChR-Ab, Musk-Ab or LRP4) on the basis of typical myasthenic symptoms;
  • Evaluated by the researcher as refractory MG. Refractory MG is defined as:
  • Treatment failed after receiving at least 2 immunosuppressants
  • Definition of treatment failure: 1) Persistent weakness and impairment of daily activities; 2) MG aggravation and/or crisis during treatment; 3) Intolerance to immunotherapy due to side effects or comorbidities;
  • Repeated plasma exchange (PE) or intravenous immune globulin (IVIg) treatment is required to control symptoms;
  • The researchers believe that despite the current routine immunotherapy for patients, MG still imposes a large functional burden on patients.
  • MGFA classification IIa\~IVa at screening and baseline;
  • QMGS score ≥11 points or MG-ADL score ≥5 points at screening and baseline, of which the eye score accounts for no more than 50%;
  • Male study participants must agree to take contraceptive measures during the treatment period and within 1 year after receiving study treatment, and are prohibited from donating sperm throughout the study period;
  • If you are a woman of childbearing potential (WOCBP), you must agree to take contraceptive measures during treatment and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result during screening; a negative urine pregnancy test result must be confirmed before receiving CART for the first time.

Exclusion Criteria:

  • Prior to screening and the baseline visit, study participants will not be eligible for inclusion in the study if they meet any of the following criteria:
  • The researcher believes that there is any medical or mental condition that may harm the research participant or affect the research participant's ability to participate in this study; or any condition that the researcher believes is related to poor compliance;
  • Women who are lactating or pregnant, or women who plan to become pregnant at any time within 12 months after receiving CART treatment, or who have a history of spontaneous abortion or induced abortion within 4 weeks before screening;
  • Study participants have clinically relevant active infections (such as sepsis, pneumonia or abscess) or serious infections (resulting in hospitalization or requiring antibiotic treatment) within 4 weeks before screening;
  • thymoma that underwent thymectomy within 6 months before baseline or was planned to undergo thymectomy during the study, or required chemotherapy and/or radiotherapy at any time;
  • Investigator participants have received live attenuated vaccine vaccination within 8 weeks before screening; or plan to receive live vaccine vaccination within 8 weeks after treatment;
  • Study participants have received rituximab treatment within 6 months before screening;
  • Have received tocilizumab or eculizumab treatment within 3 months before screening;
  • Have received intravenous human immunoglobulin, plasma exchange, or immunotherapy within 4 weeks before screening;
  • Those with known serious underlying diseases, such as liver and kidney damage, blood diseases, previous severe cardiovascular disease, severe hypertension, diabetes, and poor blood pressure and blood sugar control;
  • Unresected thymoma (Note: Subjects with benign thymoma resected more than one year before screening are eligible. Benign is defined as no known metastasis on pathological examination and no intracystic or extracystic Extension. Imaging studies must be performed during the screening period to assess thymic status).
  • Any of the following laboratory abnormalities occur during the screening period (one repeat measurement can be performed during the screening period before randomization to confirm the results)
  • Elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN)).
  • Total bilirubin>1.5 times ULN
  • Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2
  • Abnormal PT or INR, or prolonged APTT >1.5 times ULN
  • Neutrophil count <1000cell/ul
  • Platelet count <50000/mm3
  • Hemoglobin<8.0g/dl
  • Those with a high-risk history of tuberculosis infection or acquired tuberculosis infection;
  • Known immunodeficiency diseases, including human immunodeficiency virus (HIV) infection;
  • Positive for hepatitis B surface antigen (HBsAg) during the screening period;
  • Receive blood transfusion treatment 4 weeks before screening or during the screening period;
  • Symptoms worsen rapidly during the lead-in period and enter crisis or pre-crisis state (MGFA IVb-V)
  • Other circumstances in which the researcher deems it inappropriate to participate in the study.

Quoted from ClinicalTrials.gov, NCT06371040, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06371040, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06371040